Lantern Pharma Inc. (LTRN) Form 8-K — Nov 18, 2026
Lantern Pharma reported Q3 2026 results with a GAAP net income of approximately $0.7 million ($0.05/share), driven by a $6.0 million non-cash warrant gain, on a loss from…
Key figures
- Eps
- 0.05
- Cash Position
- 7600000
- Gross Proceeds
- 4000000
- Offering Price
- 1.09
- Shares Offered
- 1469725
- Shares Outstanding
- 14935576
- Cash dec 31 2025
- $10.1M
- Warrant liability
- $1.5M
- Ga expense q3 2026
- $3.8M (up 99% YoY from ~$1.9M)
- Rd expense q3 2026
- $1.6M (down 36% YoY from ~$2.4M)
- Settlement accrual
- $2.0M
- Non cash warrant gain
- $6.0M
- Net loss prior year q3
- $4.2M ($0.39/share)
- Loss from operations q3 2026
- $5.4M ($3.4M excluding settlement accrual)
- Shares outstanding nov 9 2026
- 15886576
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.